CLSD · As filed with the SEC
Clearside Biomedical income statement, by fiscal year
The statement as Clearside Biomedical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD, except per-share amounts
| USD, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 | FY2017 Year ended Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| License and other revenue (includes $321 and $5,050 from a related party for the years ended December 31, 2024 and 2023, respectively) | 1,664,000 | 8,226,000 | 1,327,000 | 29,575,000 | 7,894,000 | 2,173,000 | 30,000 | — |
| Operating expenses: | ||||||||
| Cost of goods sold | — | — | 204,000 | — | — | — | — | — |
| Cost of goods sold | 149,000 | 355,000 | — | — | — | — | — | — |
| Research and development (includes $1,051 and $1,109 to a related party for the years ended December 31, 2024 and 2023, respectively) | 18,590,000 | 20,846,000 | 19,630,000 | 18,537,000 | 15,073,000 | 15,658,000 | 68,291,000 | 49,053,000 |
| General and administrative | 11,807,000 | 11,869,000 | 11,770,000 | 11,665,000 | 10,756,000 | 16,819,000 | 14,684,000 | 9,700,000 |
| Total operating expenses | — | 33,070,000 | 31,604,000 | 30,202,000 | 25,829,000 | 32,477,000 | 82,975,000 | 58,753,000 |
| Total operating expenses | 30,546,000 | — | — | — | — | — | — | — |
| Loss from operations | (28,882,000) | (24,844,000) | (30,277,000) | (627,000) | (17,935,000) | (30,304,000) | (82,945,000) | (58,408,000) |
| Other (expense) income | — | — | — | — | (275,000) | (466,000) | 127,000 | (567,000) |
| Interest income | 1,462,000 | — | — | — | — | — | — | — |
| Other income, net | 2,847,000 | 1,719,000 | 669,000 | 1,003,000 | — | — | — | — |
| Non-cash interest expense on liability related to the sales of future royalties | (9,779,000) | (9,360,000) | (3,339,000) | — | — | — | — | — |
| Other expense | — | — | 0 | 0 | — | — | — | — |
| Net loss | (34,352,000) | (32,485,000) | (32,947,000) | 376,000 | (18,210,000) | (30,770,000) | (82,818,000) | (58,975,000) |
| Net income (loss) per share of common stock - basic and diluted | — | — | — | 0.01 | (0.39) | (0.81) | (2.69) | (2.33) |
| Weighted average shares outstanding — basic and diluted | — | — | — | — | 46,506,540 | 38,170,830 | 30,733,600 | 25,311,614 |
| Unrealized gain on available-for-sale investments | — | — | — | — | — | — | — | 5,000 |
| Comprehensive loss | — | — | — | — | — | (30,770,000) | (82,818,000) | (58,970,000) |
| Net loss per share of common stock - basic | (0.47) | (0.53) | (0.55) | — | — | — | — | — |
| Net loss per share of common stock - diluted | (0.47) | (0.53) | (0.55) | — | — | — | — | — |
| Weighted average shares outstanding - basic | 73,803,348 | 61,806,959 | 60,204,862 | 58,491,986 | — | — | — | — |
| Weighted average shares outstanding - diluted | 73,803,348 | 61,806,959 | 60,204,862 | 59,906,602 | — | — | — | — |
| License and collaboration revenue | — | — | — | — | — | — | — | 345,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.